The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Bilateral visual improvement with unilateral gene therapy injection for Leber hereditary optic neuropathy
Open accessAbstract
At 96 weeks after unilateral intravitreal injection of rAAV2/2- ND4 , vision improved in both eyes in 78% of subjects affected with LHON.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Among RESCUE subjects, BCVA evolution was comparable in both rAAV2/2-ND4etreated and shamtreated eyes, similar to the bilateral changes seen among subjects in the REVERSE study.18”
From Efficacy and Safety of Intravitreal Gene Therapy for Leber Hereditary Optic Neuropathy Treated within 6 Months of Disease Onset (2021) · cites this paper as [18]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A total of 78% of patients experienced some bilateral improvement of BCVA from baseline; 81% experienced a CRR from nadir in at least 1 eye, and 76% had an improvement of at least À0.3 logMAR (15 ETDRS letters equivalent) from nadir in at least 1 eye.”
From Efficacy and Safety of Intravitreal Gene Therapy for Leber Hereditary Optic Neuropathy Treated within 6 Months of Disease Onset (2021) · cites this paper as [18]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It is also the first clinical study assessing the efficacy of a bilateral IVT of lenadogene nolparvovec, while in the three previous clinical studies REVEAL,21 REVERSE16–18 and RESCUE,17–19 lenadogene nolparvovec was exclusively administered as unilateral IVT.”
From Randomized trial of bilateral gene therapy injection for m.11778G>A MT-ND4 Leber optic neuropathy (2023) · cites this paper as [16]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The REVERSE (NCT02652780), RESCUE (NCT02652767), and REFLECT (NCT03293524) Phase III studies in LHON all reported a similar inci dence of intraocular inflammation with the same construct and dose of AAV vector despite different prophylaxis regimes.”
From Gene Therapy-Associated Uveitis (GTAU): Understanding and mitigating the adverse immune response in retinal gene therapy (2025) · cites this paper as Yu-Wai-Man et al., 2020
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In the REVERSE trial, LHON subjects had loss of vision in both eyes of 6 months to 1 year at study enrollment, and a bilateral visual improvement was observed over the 96 weeks after treatment administration.18”
From Efficacy and Safety of Intravitreal Gene Therapy for Leber Hereditary Optic Neuropathy Treated within 6 Months of Disease Onset (2021) · cites this paper as [18]
The cited source says what the claim attributes to it.
In the citing paper
“RESCUE and REVERSE 18 are not the only studies to report bilateral BCVA improvement after unilateral injection of gene therapy.”
From Efficacy and Safety of Intravitreal Gene Therapy for Leber Hereditary Optic Neuropathy Treated within 6 Months of Disease Onset (2021) · cites this paper as [18]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In the REVERSE study, at week 96, rAAV2/2-ND4etreated eyes showed a LS mean improvement from baseline in BCVA of À0.308 logMAR (þ15 ETDRS letters equivalent), and sham-treated eyes showed an LS mean improvement from baseline of À0.259 logMAR (þ13 ETDRS letters equivalent).18”
From Efficacy and Safety of Intravitreal Gene Therapy for Leber Hereditary Optic Neuropathy Treated within 6 Months of Disease Onset (2021) · cites this paper as [18]
The cited source says what the claim attributes to it.
In the citing paper
“This study suggested there is some transfer of viral vector DNA from the injected eyes to the uninjected contralateral eyes after unilateral lenadogene IVT.”
From Randomized trial of bilateral gene therapy injection for m.11778G>A MT-ND4 Leber optic neuropathy (2023) · cites this paper as [16]
The cited source says what the claim attributes to it.
In the citing paper
“The absence of systemic issues related to lenadogene nolparvovec treatment is supported by the limited biodissemination of the product, which is negligible in the blood of REFLECT patients, similar to what has been observed in previous clinical studies.16,19”
From Randomized trial of bilateral gene therapy injection for m.11778G>A MT-ND4 Leber optic neuropathy (2023) · cites this paper as [16]
In the citing paper
“RESCUE and REVERSE (ClinicalTrial.gov NCT02652767 and NCT026527080) (15,16) were 2 randomized, double-masked, sham-controlled, multicenter, international, pivotal clinical trials to evaluate the efficacy of a single IVT of rAAV2/2-ND4 in subjects with LHON secondary to the m.11778G>A mutation.”
From Cross-sectional analysis of baseline visual parameters in subjects recruited into the RESCUE and REVERSE ND4-LHON gene therapy studies (2021) · cites this paper as [16]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2005) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2005.03.057 · Cited by 4,396
Russell, S., Bennett, J., Wellman, J. A., Chung, D. C., Yu, Z.-F., Tillman, A., Wittes, J., Pappas, J., Elci, O., McCague, S., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31868-8 · Cited by 1,952
Proper Method for Calculating Average Visual Acuity
Holladay, J. T. (1997) · Journal of Refractive Surgery · doi:10.3928/1081-597x-19970701-16 · Cited by 1,097
Zingg, B., Chou, X.-L., Zhang, Z., Mesik, L., Liang, F., Tao, H. W., & Zhang, L. I. (2016) · Neuron · doi:10.1016/j.neuron.2016.11.045 · Cited by 775
Standardizatlon of Vitreal inflammatory Activity in Intermediate and Posterior Uveitis
Nussenblatt, R. B., Palestine, A. G., Chan, C.-C., & Roberge, F. (1985) · Ophthalmology · doi:10.1016/s0161-6420(85)34001-0 · Cited by 684
A randomized placebo-controlled trial of idebenone in Leber’s hereditary optic neuropathy.
Klopstock, T., Yu-Wai-Man, P., Dimitriadis, K., Rouleau, J., Heck, S., Bailie, M., Atawan, A., Chattopadhyay, S., Schubert, M., Garip, A., et al. (2011) · Brain · doi:10.1093/brain/awr170 · Cited by 578
Self-citationSingle-cell analysis of experience-dependent transcriptomic states in the mouse visual cortex
Hrvatin, S., Hochbaum, D. R., Nagy, M. A., Cicconet, M., Robertson, K., Cheadle, L., Zilionis, R., Ratner, A., Borges-Monroy, R., Klein, A. M., et al. (2018) · Nature Neuroscience · doi:10.1038/s41593-017-0029-5 · Cited by 497
The Epidemiology of Leber Hereditary Optic Neuropathy in the North East of England
Yu‐Wai‐Man, P., Griffiths, P. G., Brown, D. T., Howell, N., Turnbull, D. M., & Chinnery, P. F. (2003) · The American Journal of Human Genetics · doi:10.1086/346066 · Cited by 485
Self-citationNewman, N. J., Lott, M. T., & Wallace, D. C. (1991) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(14)76784-4 · Cited by 403
Self-citationGiordano, C., Iommarini, L., Giordano, L., Maresca, A., Pisano, A., Valentino, M. L., Caporali, L., Liguori, R., Deceglie, S., Roberti, M., et al. (2013) · Brain · doi:10.1093/brain/awt343 · Cited by 282
Self-citation
Cited by
Sorted by citations
Apolipoprotein E: Structural Insights and Links to Alzheimer Disease Pathogenesis
Chen, Y., Strickland, M. R., Soranno, A., & Holtzman, D. M. (2021) · Neuron · doi:10.1016/j.neuron.2020.10.008 · Cited by 298
Mitochondrial disease in adults: recent advances and future promise
Ng, Y. S., Bindoff, L. A., Gorman, G. S., Klopstock, T., Kornblum, C., Mancuso, M., McFarland, R., Sue, C. M., Suomalainen, A., Taylor, R. W., et al. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00098-3 · Cited by 229
Self-citationMitochondrial function in development and disease
Rossmann, M. P., Dubois, S. M., Agarwal, S., & Zon, L. I. (2021) · Disease Models & Mechanisms · doi:10.1242/dmm.048912 · Cited by 200
Newman, N. J., Yu-Wai-Man, P., Carelli, V., Moster, M. L., Biousse, V., Vignal-Clermont, C., Sergott, R. C., Klopstock, T., Sadun, A. A., Barboni, P., et al. (2021) · Ophthalmology · doi:10.1016/j.ophtha.2020.12.012 · Cited by 168
“650 In the REVERSE trial, LHON subjects had loss of vision in both eyes of 6 months to 1 year at study enrollment, and a bilateral visual improvement was observed over the 96 weeks after treatment administration.(18) The RESCUE trial was designed concurrently with the REVERSE trial with similar assessment protocols an…”
BackgroundMethodResultInfluentialSelf-citationRetinal Ganglion Cells—Diversity of Cell Types and Clinical Relevance
Kim, U. S., Mahroo, O. A., Mollon, J. D., & Yu‐Wai‐Man, P. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.661938 · Cited by 157
Self-citationImmunomodulatory Role of the Extracellular Matrix Within the Liver Disease Microenvironment
McQuitty, C. E., Williams, R., Chokshi, S., & Urbani, L. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.574276 · Cited by 146
The potential of mitochondrial genome engineering
Silva-Pinheiro, P., & Minczuk, M. A. (2021) · Nature Reviews Genetics · doi:10.1038/s41576-021-00432-x · Cited by 142
Immunotherapy Goes Local: The Central Role of Lymph Nodes in Driving Tumor Infiltration and Efficacy
van Pul, K. M., Fransen, M. F., van de Ven, R., & de Gruijl, T. D. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.643291 · Cited by 105
Newman, N. J., Yu-Wai-Man, P., Biousse, V., & Carelli, V. (2023) · The Lancet Neurology · doi:10.1016/s1474-4422(22)00174-0 · Cited by 97
Self-citationRandomized trial of bilateral gene therapy injection for m.11778G>A MT-ND4 Leber optic neuropathy
Newman, N. J., Yu-Wai-Man, P., Subramanian, P. S., Moster, M. L., Wang, A.-G., Donahue, S. P., Leroy, B. P., Carelli, V., Biousse, V., Vignal-Clermont, C., et al. (2023) · Brain · doi:10.1093/brain/awac421 · Cited by 87
“The physiologic basis of the contralateral effect of unilateral lenadogene nolparvovec IVT has been investigated in a mechanistic study conducted in non-human primates.(16,33) This study suggested there is some transfer of viral vector DNA from the injected eyes to the uninjected contralateral eyes after unilateral le…”
InfluentialSelf-citationZeviani, M., & Carelli, V. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010210 · Cited by 87
Self-citationLeber Hereditary Optic Neuropathy: Review of Treatment and Management
Hage, R., & Vignal‐Clermont, C. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.651639 · Cited by 80
Self-citationNieuwenhuis, B., Laperrousaz, E., Tribble, J. R., Verhaagen, J., Fawcett, J. W., Martin, K. R. G., Williams, P. A., & Osborne, A. (2023) · Gene Therapy · doi:10.1038/s41434-022-00380-z · Cited by 81
DB-OTO Gene Therapy for Inherited Deafness
Valayannopoulos, V., Bance, M., Carvalho, D., Greinwald, J. H., Harvey, S. A., Ishiyama, A., Landry, E. C., Löwenheim, H., Lustig, L. R., Manrique, M. J., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2400521 · Cited by 76
Cytokine engineering for targeted cancer immunotherapy
Bonati, L., & Tang, L. (2021) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2021.01.007 · Cited by 76
Natural history of patients with Leber hereditary optic neuropathy—results from the REALITY study
Yu‐Wai‐Man, P., Newman, N. J., Carelli, V., Morgia, C. L., Biousse, V., Bandello, F. M., Vignal‐Clermont, C., Castillo, L., Leruez, S., Moster, M. L., et al. (2021) · Eye · doi:10.1038/s41433-021-01535-9 · Cited by 74
Self-citationBiousse, V., Newman, N. J., Yu-Wai-Man, P., Carelli, V., Moster, M. L., Vignal-Clermont, C., Klopstock, T., Sadun, A. A., Sergott, R. C., Hage, R., et al. (2021) · Journal of Neuro-Ophthalmology · doi:10.1097/wno.0000000000001367 · Cited by 78
Self-citationBritten‐Jones, A. C., Jin, R., Gocuk, S. A., Cichello, E., O’Hare, F., Hickey, D. G., Edwards, T. L., & Ayton, L. N. (2021) · Genetics in Medicine · doi:10.1016/j.gim.2021.10.013 · Cited by 67
Newman, N. J., Yu-Wai-Man, P., Carelli, V., Biousse, V., Moster, M. L., Vignal-Clermont, C., Sergott, R. C., Klopstock, T., Sadun, A. A., Girmens, J.-F., et al. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.662838 · Cited by 64
Self-citationElbadawi, M. M., Eldehna, W. M., Wang, W., Agama, K., Pommier, Y. G., & Abe, M. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113261 · Cited by 63
Engineered mitochondria in diseases: mechanisms, strategies, and applications
Li, M., Wu, L., Si, H., Wu, Y., Liu, Y., Zeng, Y., & Shen, B. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02081-y · Cited by 71
Nanobiomaterial vectors for improving gene editing and gene therapy
Hu, S. W., Ding, T., Tang, H., Guo, H., Cui, W., & Shu, Y. (2023) · Materials Today · doi:10.1016/j.mattod.2023.04.011 · Cited by 58
Gene Therapy for Mitochondrial Diseases: Current Status and Future Perspective
Donfrancesco, A. D., Massaro, G., Meo, I. D., Tiranti, V., Bottani, E., & Brunetti, D. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14061287 · Cited by 62
Adeno-Associated Virus Vector for Central Nervous System Gene Therapy
Zhu, D., Schieferecke, A. J., Lopez, P. A., & Schaffer, D. V. (2021) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2021.03.010 · Cited by 56
Applying genomic and transcriptomic advances to mitochondrial medicine
Macken, W. L., Vandrovcová, J., Hanna, M. G., & Pitceathly, R. D. S. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-021-00455-2 · Cited by 56
Vignal-Clermont, C., Girmens, J.-F., Audo, I., Said, S. M., Errera, M.-H., Plaine, L., O’Shaughnessy, D., Taiel, M., & Sahel, J.-A. (2021) · BioDrugs · doi:10.1007/s40259-021-00468-9 · Cited by 51
Self-citationKlopstock, T., Priglinger, C., Yılmaz, A., Kornblum, C., Distelmaier, F., & Prokisch, H. (2021) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.m2021.0251 · Cited by 57
Self-citationCommon methods in mitochondrial research (Review)
Yin, Y., & Shen, H. (2022) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2022.5182 · Cited by 52
Mitochondria in Retinal Ganglion Cells: Unraveling the Metabolic Nexus and Oxidative Stress
Yang, T.-H., Kang, E. Y., Lin, P., Yu, B. B.-C., Wang, J. H.-H., Chen, V., & Wang, N. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25168626 · Cited by 59
Update on viral gene therapy clinical trials for retinal diseases
Cheng, S.-Y., & Punzo, C. (2022) · Human Gene Therapy · doi:10.1089/hum.2022.159 · Cited by 49
Wang, J.-H., Zhan, W., Gallagher, T. L., & Gao, G. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.10.017 · Cited by 51
Mitochondrial optic neuropathies
Carelli, V., Morgia, C. L., & Yu‐Wai‐Man, P. (2023) · Handbook of clinical neurology · doi:10.1016/b978-0-12-821751-1.00010-5 · Cited by 47
Self-citationLeber hereditary optic neuropathy—new insights and old challenges
Sundaramurthy, S., Selvakumar, A., Ching, J., Dharani, V., Sarangapani, S., & Yu‐Wai‐Man, P. (2020) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-020-04993-1 · Cited by 49
Self-citationSladen, P. E., Perdigão, P. R. L., Salsbury, G., Novoselova, T. V., van der Spuy, J., Chapple, J. P., Yu‐Wai‐Man, P., & Cheetham, M. E. (2021) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2021.08.015 · Cited by 47
Self-citationNew Insights into Mitochondria in Health and Diseases
Li, Y., Zhang, H., Yu, C., Dong, X., Yang, F., Wang, M., Wen, Z., Su, M., Li, B., & Yang, L. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25189975 · Cited by 48
Saluzzo, S., Pandey, R. V., Gail, L. M., Dingelmaier‐Hovorka, R., Kleißl, L., Shaw, L. E., Reininger, B., Atzmüller, D., Strobl, J., Touzeau‐Römer, V., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.10.021 · Cited by 46
Lam, B. L., Feuer, W. J., Davis, J. L., Porciatti, V., Yu, H., Levy, R. B., Vanner, E., & Guy, J. (2022) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2022.02.023 · Cited by 43
Modeling mitochondrial DNA diseases: from base editing to pluripotent stem‐cell‐derived organoids
Tolle, I., Tiranti, V., & Prigione, A. (2023) · EMBO Reports · doi:10.15252/embr.202255678 · Cited by 43
Gene therapy for primary mitochondrial diseases: experimental advances and clinical challenges
Falabella, M., Minczuk, M. A., Hanna, M. G., Viscomi, C. F., & Pitceathly, R. D. S. (2022) · Nature Reviews Neurology · doi:10.1038/s41582-022-00715-9 · Cited by 42
Developments in the Treatment of Leber Hereditary Optic Neuropathy
Chen, B. S., Yu‐Wai‐Man, P., & Newman, N. J. (2022) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-022-01246-y · Cited by 41
Self-citationMitochondria and the eye—manifestations of mitochondrial diseases and their management
Chen, B. S., Harvey, J. P., Gilhooley, M. J., Jurkutė, N., & Yu‐Wai‐Man, P. (2023) · Eye · doi:10.1038/s41433-023-02523-x · Cited by 39
Self-citationMitochondrial DNA disorders: from pathogenic variants to preventing transmission
Gomes, T. M. B., Ng, Y. S., Pickett, S. J., Turnbull, D. M., & Vincent, A. E. (2021) · Human Molecular Genetics · doi:10.1093/hmg/ddab156 · Cited by 42
Biodistribution of intravitreal lenadogene nolparvovec gene therapy in nonhuman primates
Calkins, D. J., Yu-Wai-Man, P., Newman, N. J., Taiel, M., Singh, P., Chalmey, C., Rogue, A., Carelli, V., Ancian, P., & Sahel, J. A. (2021) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2021.09.013 · Cited by 37
Self-citationEndocrine Manifestations and New Developments in Mitochondrial Disease
Ng, Y. S., Lim, A. Z., Panagiotou, G., Turnbull, D. M., & Walker, M. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnab036 · Cited by 37
Constable, P. A., Marmolejo‐Ramos, F., Gauthier, M., Lee, I., Skuse, D., & Thompson, D. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.890461 · Cited by 39
Autosomal recessive Leber hereditary optic neuropathy, a new neuro-ophthalmo-genetic paradigm
Lenaers, G., Beaulieu, C., Charif, M., Gerber, S., Kaplan, J., & Rozet, J. (2023) · Brain · doi:10.1093/brain/awad131 · Cited by 37
Sobh, M., Lagali, P. S., Ghiasi, M., Montroy, J. R., Dollin, M. L., Hurley, B. R., Leonard, B. C., Dimopoulos, I. S., Lafreniere, M., Fergusson, D. A., et al. (2023) · Translational Vision Science & Technology · doi:10.1167/tvst.12.11.24 · Cited by 35
Gene therapy for mitochondrial disorders
Keshavan, N., Minczuk, M. A., Viscomi, C. F., & Rahman, S. (2024) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12699 · Cited by 39
Khatib, T. Z., Osborne, A., Yang, S., Ali, Z., Jia, W., Manyakin, I., Hall, K., Watt, R., Widdowson, P. S., & Martin, K. R. G. (2021) · Science Advances · doi:10.1126/sciadv.abd2590 · Cited by 35
Update on Clinical Trial Endpoints in Gene Therapy Trials for Inherited Retinal Diseases
Igoe, J., Lam, B. L., & Gregori, N. Z. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13185512 · Cited by 33
Five-Year Outcomes of Lenadogene Nolparvovec Gene Therapy in Leber Hereditary Optic Neuropathy
Yu‐Wai‐Man, P., Newman, N. J., Biousse, V., Carelli, V., Moster, M. L., Vignal‐Clermont, C., Klopstock, T., Sadun, A. A., Sergott, R. C., Hage, R., et al. (2024) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2024.5375 · Cited by 33
Self-citationA synthetic opsin restores vision in patients with severe retinal degeneration
Mohanty, S. K., Mahapatra, S., Batabyal, S., Carlson, M. E., Kanungo, G., Ayyagari, A. L., Tchedre, K. T., Franco, J. A., Singer, M. A., Barone, S. B., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.031 · Cited by 41
Carelli, V., Newman, N. J., Yu‐Wai‐Man, P., Biousse, V., Moster, M. L., Subramanian, P. S., Vignal‐Clermont, C., Wang, A.-G., Donahue, S. P., Leroy, B. P., et al. (2022) · Ophthalmology and Therapy · doi:10.1007/s40123-022-00611-x · Cited by 30
Self-citationStrategies to improve safety profile of AAV vectors
Suoranta, T., Laham-Karam, N., & Ylä‐Herttuala, S. (2022) · Frontiers in Molecular Medicine · doi:10.3389/fmmed.2022.1054069 · Cited by 32
Leber’s hereditary optic neuropathy: Update on current diagnosis and treatment
Esmaeil, A., Ali, A., & Behbehani, R. S. (2023) · Frontiers in Ophthalmology · doi:10.3389/fopht.2022.1077395 · Cited by 28
Gene Therapies for the Treatment of Leber Hereditary Optic Neuropathy
Sahel, J., Newman, N. J., Yu‐Wai‐Man, P., Vignal‐Clermont, C., Carelli, V., Biousse, V., Moster, M. L., Sergott, R. C., Klopstock, T., Sadun, A. A., et al. (2021) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000364 · Cited by 28
Self-citationFerla, R., Dell’Aquila, F., Doria, M., Ferraiuolo, M. A., Noto, A., Grazioli, F., Ammendola, V., Testa, F., Melillo, P., Iodice, C., et al. (2023) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2023.02.002 · Cited by 29
VIGNAL-CLERMONT, C., YU-WAI-MAN, P., NEWMAN, N. J., CARELLI, V., MOSTER, M. L., BIOUSSE, V., SUBRAMANIAN, P. S., WANG, A.-G., DONAHUE, S. P., LEROY, B. P., et al. (2023) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2022.11.026 · Cited by 25
Self-citationCurrent and Future Landscape in Genetic Therapies for Leber Hereditary Optic Neuropathy
Shamsnajafabadi, H., MacLaren, R. E., & Cehajic‐Kapetanovic, J. (2023) · Cells · doi:10.3390/cells12152013 · Cited by 27
Wang, Y., Yang, J.-S., Zhao, M., Chen, J., Xie, H.-X., Yu, H., Liu, N.-H., Yi, Z.-J., Liang, H., Xing, L., et al. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115355 · Cited by 26
Harnessing Biomaterials and the Lymphatic System for ImmunomodulationPreprint
Alderfer, L., Hall, E., & Hanjaya‐Putra, D. (2020) · SSRN Electronic Journal · doi:10.1016/j.actbio.2021.06.006 · Cited by 26
Xu, N., Xu, T., Mirasol, R. V., Holmberg, L., Vincent, P. H., Li, X., Falk, A., Benedikz, E., Rotstein, E., Seiger, Å., et al. (2021) · Neurotherapeutics · doi:10.1007/s13311-020-00987-3 · Cited by 25
Purdy, R., John, M., Bray, A., Clare, A. J., Copland, D. A., Chan, Y. K., Henderson, R. H., Nerinckx, F., Leroy, B. P., Yang, P., et al. (2025) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2025.101354 · Cited by 24
Prostaglandin-based rAAV-mediated glaucoma gene therapy in Brown Norway rats
Chern, K. J., Nettesheim, E. R., Reid, C. A., Li, N. W., Marcoe, G. J., & Lipinski, D. M. (2022) · Communications Biology · doi:10.1038/s42003-022-04134-w · Cited by 24
Borrelli, E., Bandello, F. M., Boon, C. J. F., Carelli, V., Lenaers, G., Reibaldi, M., Sadda, S. R., Sadun, A. A., Sarraf, D., Yu‐Wai‐Man, P., et al. (2024) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2024.101264 · Cited by 25
Self-citationFrancis, D. M., Manspeaker, M. P., Archer, P. A., Sestito, L. F., Heiler, A. J., Schudel, A., & Thomas, S. N. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.121184 · Cited by 24
OPA1 Dominant Optic Atrophy: Pathogenesis and Therapeutic Targets
Wong, D., Harvey, J. P., Jurkutė, N., Thomasy, S. M., Moosajee, M., Yu‐Wai‐Man, P., & Gilhooley, M. J. (2023) · Journal of Neuro-Ophthalmology · doi:10.1097/wno.0000000000001830 · Cited by 24
Self-citationAAV-vector based gene therapy for mitochondrial disease: progress and future perspectives
Hanaford, A. R., Cho, Y., & Nakai, H. (2022) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-022-02324-7 · Cited by 25
Macken, W. L., Falabella, M., Pizzamiglio, C., Woodward, C. E., Scotchman, E., Chitty, L. S., Polke, J. M., Bugiardini, E., Hanna, M. G., Vandrovcová, J., et al. (2023) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2023.2241365 · Cited by 23
Wolfram syndrome: new pathophysiological insights and therapeutic strategies
Mishra, R., Chen, B. S., Richa, P., & Yu‐Wai‐Man, P. (2021) · Therapeutic Advances in Rare Disease · doi:10.1177/26330040211039518 · Cited by 25
Self-citationMaulloo, C. D., Cao, S., Watkins, E. A., Raczy, M. M., Solanki, A., Nguyen, M., Reda, J. W., Shim, H.-N., Wilson, D. S., Swartz, M. A., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.714842 · Cited by 20
Newman, N. J., Biousse, V., Yu‐Wai‐Man, P., Carelli, V., Vignal‐Clermont, C., Montestruc, F., Taiel, M., & Sahel, J. (2024) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2024.10.002 · Cited by 20
Self-citationWhite, K. A., Nelvagal, H. R., Poole, T. A., Lü, B., Johnson, T. B., Davis, S. S., Pratt, M. A., Brudvig, J. J., Assis, A. B., Likhite, S. B., et al. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.12.014 · Cited by 19
Liu, Y., Eastwood, J. D., Alba, D. E., Velmurugan, S., Sun, N., Porciatti, V., Lee, R. K., Hauswirth, W. W., Guy, J., & Yu, H. (2022) · Gene Therapy · doi:10.1038/s41434-022-00333-6 · Cited by 19
Devi, S. M., Abishek Kumar, B., Iyer, M., & Vellingiri, B. (2021) · Mitochondrion · doi:10.1016/j.mito.2021.08.013 · Cited by 18
The Present and Future of Mitochondrial-Based Therapeutics for Eye Disease
Ji, M. H., Kreymerman, A., Belle, K. C., Ghiam, B. K., Muscat, S. P., Mahajan, V. B., Enns, G. M., Mercola, M. A., & Wood, E. H. (2021) · Translational Vision Science & Technology · doi:10.1167/tvst.10.8.4 · Cited by 18
Neuroimaging in Leber Hereditary Optic Neuropathy: State-of-the-art and future prospects
Chow-Wing-Bom, H. T., Callaghan, M. F., Wang, J., Wei, S., Dick, F., Yu‐Wai‐Man, P., & Dekker, T. M. (2022) · NeuroImage Clinical · doi:10.1016/j.nicl.2022.103240 · Cited by 18
Self-citationSpiegel, S. J., & Sadun, A. A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113205 · Cited by 18
Self-citationLate-Onset Retinal Degeneration: Clinical Perspectives
Landó, L., & Borooah, S. (2022) · Clinical ophthalmology · doi:10.2147/opth.s362691 · Cited by 17
McGrady, N. R., Boal, A. M., Risner, M. L., Taiel, M., Sahel, J., & Calkins, D. J. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.03.035 · Cited by 16
Self-citationLam, B. L., Feuer, W. J., Porciatti, V., Davis, J. L., Zheng, D., Vanner, E. A., Savatovsky, E. J., Alba, D. E., & Guy, J. R. (2023) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2023.09.005 · Cited by 17
Therapies for Mitochondrial Disease: Past, Present, and Future
Ball, M., Bergen, N. J. V., Compton, A. G., Thorburn, D. R., Rahman, S., & Christodoulou, J. (2025) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.70065 · Cited by 21
Chen, J., Chen, C., Chen, J., Ji, Y., Lian, Y., Zhang, J., Yu, J., Li, X., Qu, J., & Guan, M. (2023) · Human Molecular Genetics · doi:10.1093/hmg/ddad001 · Cited by 15
From Transcriptomics to Treatment in Inherited Optic Neuropathies
Gilhooley, M. J., Owen, N., Moosajee, M., & Yu‐Wai‐Man, P. (2021) · Genes · doi:10.3390/genes12020147 · Cited by 17
Self-citationGene Therapy for Inherited Retinal Disorders: Update on Clinical Trials
Michalakis, S., Gerhardt, M. J., Rudolph, G., Priglinger, S. G., & Priglinger, C. (2021) · Klinische Monatsblätter für Augenheilkunde · doi:10.1055/a-1384-0818 · Cited by 15
Self-citationPeron, C., Maresca, A., Cavaliere, A., Iannielli, A., Broccoli, V., Carelli, V., Meo, I. D., & Tiranti, V. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.648916 · Cited by 15
Self-citationScaffold-free and scaffold-based cellular strategies and opportunities for cornea tissue engineering
Hussain, Z., & Pei, R. (2021) · Progress in Biomedical Engineering · doi:10.1088/2516-1091/ac12d7 · Cited by 15
Red Flags in Primary Mitochondrial Diseases: What Should We Recognize?
Conti, F., Martino, S. D., Drago, F., Bucolo, C., Micale, V., Montano, V., Siciliano, G., Mancuso, M., & Lopriore, P. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242316746 · Cited by 14
Thomas, R. H., Hunter, A., Butterworth, L., Feeney, C. L., Graves, T. D., Holmes, S. L., Hossain, P., Lowndes, J., Sharpe, J. A., Upadhyaya, S., et al. (2022) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12521 · Cited by 14
The clinical safety landscape for ocular AAV gene therapies: A systematic review and meta-analysis
Liu, Z., Zhang, H., Jia, H., Wang, H., Huang, Z., Tang, Y., Wang, Z., Hu, J., Zhao, X., Li, T., et al. (2025) · iScience · doi:10.1016/j.isci.2025.112265 · Cited by 15
Cruz-Pavlovich, F. J. S., Bolaños-Chang, A. J., Rio-Murillo, X. I. D., Aranda-Preciado, G. A., Razura-Ruiz, E. M., Santos, A., & Navarro‐Partida, J. (2024) · Cells · doi:10.3390/cells13020179 · Cited by 13
Leber hereditary optic neuropathy: new and emerging therapies
Davila-Siliezar, P. A., Carter, M. W., Miléa, D., & Lee, A. G. (2022) · Current Opinion in Ophthalmology · doi:10.1097/icu.0000000000000891 · Cited by 13
Chen, X., Chen, M., Zhu, Y., Sun, H., Wang, Y., Xie, Y., Ji, L., Wang, C., Hu, Z., Guo, X., et al. (2023) · Communications Biology · doi:10.1038/s42003-023-05500-y · Cited by 13
Gilmore, W. B., Hultgren, N. W., Chadha, A., Barocio, S. B., Zhang, J., Kutsyr, O., Flores‐Bellver, M., Canto-Soler, M. V., & Williams, D. S. (2023) · Vision Research · doi:10.1016/j.visres.2023.108311 · Cited by 14
Current progress in the therapeutic options for mitochondrial disorders.
Koňaříková, E., Markovic, A., Korandová, Z., Houštěk, J., & Mráček, T. (2020) · Physiological Research · doi:10.33549/physiolres.934529 · Cited by 13
Therapeutic landscape for inherited ocular diseases: current and emerging therapies
Chan, H. W., Oh, J., & Leroy, B. P. (2023) · Singapore Medical Journal · doi:10.4103/singaporemedj.smj-2022-179 · Cited by 13
Gene Therapy: A Possible Alternative to CFTR Modulators?
Mercier, J., Ruffin, M., Corvol, H., & Guillot, L. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.648203 · Cited by 13
From Bench to Bedside—Delivering Gene Therapy for Leber Hereditary Optic NeuropathyPreprint
Chen, B. S., & Yu‐Wai‐Man, P. (2022) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041282 · Cited by 12
Self-citationClinical trials in Leber hereditary optic neuropathy: outcomes and opportunities
Chen, B. S., & Newman, N. J. (2024) · Current Opinion in Neurology · doi:10.1097/wco.0000000000001343 · Cited by 11
Self-citationStephenson, K. A. J., McAndrew, J., Kenna, P. F., & Cassidy, L. (2022) · Neuro-Ophthalmology · doi:10.1080/01658107.2022.2032761 · Cited by 11
Metadata
- Authors
- Yu-Wai-Man, P., Newman, N. J., Carelli, V., Moster, M. L., Biousse, V., Sadun, A. A., Klopstock, T., Vignal-Clermont, C., Sergott, R. C., Rudolph, G., La Morgia, C., Karanjia, R., Taiel, M., Blouin, L., Burguière, P., Smits, G., Chevalier, C., Masonson, H., Salermo, Y., Katz, B., Picaud, S., Calkins, D. J., & Sahel, J.-A.
- Affiliations
- Cambridge Centre for Brain Repair and MRC Mitochondrial Biology Unit, Department of Clinical Neurosciences, University of Cambridge, Cambridge CB2 0PY, UK.
- Emory University (US)
- IRCCS Istituto delle Scienze Neurologiche di Bologna, UOC Clinica Neurologica, 40139 Bologna, Italy.
- Thomas Jefferson University (US)
- Departments of Ophthalmology, Neurology and Neurological Surgery, Emory University School of Medicine, Atlanta, GA 30322, USA.
- University of California, Los Angeles (US)
- German Center for Neurodegenerative Diseases (DE)
- Department of Neuro-Ophthalmology and Emergencies, Rothschild Foundation Hospital, 75019 Paris, France.
- LMU Klinikum (DE)
- University of Ottawa (CA)
- GenSight Biologics (France) (FR)
- GenSight Biologics, New York, NY 10016, USA.
- Centre National de la Recherche Scientifique (FR)
- Vanderbilt University Medical Center (US)
- Corresponding author
- Sahel, José-Alain
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2020-12-09
- Volume
- 12
- Issue
- 573
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W3112356895
- Semantic Scholar
- 2da05deb776c7a779083c86633384a37dd820660
- Cited by
- 232
- References
- 44
- Citations by year
- 2026: 23 · 2025: 39 · 2024: 34 · 2023: 39 · 2022: 42 · 2021: 49 · 2020: 5
- FWCI
- 10.95
- Type
- journal article
- Language
- en
- Open access
- Licence
- other-oa
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion, other-oa)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion, cc-by-nd)
- DZNE Pub (submittedVersion)
- Apollo (University of Cambridge) (submittedVersion)
- Apollo
- Funders
- GenSight Biologics
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Ophthalmology › Glaucoma and retinal disorders
- Keywords
- Leber's hereditary optic neuropathy, gene therapy, unilateral injection, nonhuman primate model, visual recovery, optic nerve, retina, anterior segment
- MeSH terms
- Dependovirus, Animals, Humans, NADH Dehydrogenase, Visual Acuity, Visual Fields, Genetic Therapy, Optic Atrophy, Hereditary, Leber, Tomography, Optical Coherence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
